Collegium Pharmaceutical Inc. (NASDAQ:COLL) rose 4.6% during mid-day trading on Thursday . The company traded as high as $8.84 and last traded at $8.71, with a volume of 118,884 shares. The stock had previously closed at $8.33.

COLL has been the topic of a number of recent analyst reports. Zacks Investment Research raised Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a report on Tuesday, May 24th. Piper Jaffray Cos. reissued an “overweight” rating and set a $26.00 target price on shares of Collegium Pharmaceutical in a report on Thursday, May 26th. Finally, Needham & Company LLC reissued a “buy” rating and set a $30.00 target price (up from $28.00) on shares of Collegium Pharmaceutical in a report on Thursday, May 26th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $28.25.

The firm’s market capitalization is $211.28 million. The company has a 50 day moving average of $11.34 and a 200-day moving average of $15.29.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its earnings results on Wednesday, August 10th. The specialty pharmaceutical company reported ($1.05) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.76) by $0.29. Equities analysts forecast that Collegium Pharmaceutical Inc. will post ($3.88) EPS for the current fiscal year.

In other news, Director John A. Fallon acquired 2,375 shares of the business’s stock in a transaction dated Friday, August 12th. The stock was purchased at an average cost of $10.59 per share, for a total transaction of $25,151.25. Following the acquisition, the director now owns 2,375 shares of the company’s stock, valued at $25,151.25. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is developing and planning to commercialize abuse-deterrent products that include its DETERx platform technology for the treatment of chronic pain and other diseases. The Company’s lead product candidate, Xtampza ER (Xtampza) is an abuse-deterrent, extended-release, oral formulation of oxycodone, opioid medication.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.